These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 10082123)

  • 1. Passively administered neutralizing serum that protected macaques against infection with parenterally inoculated pathogenic simian-human immunodeficiency virus failed to protect against mucosally inoculated virus.
    Joag SV; Li Z; Wang C; Foresman L; Jia F; Stephens EB; Zhuge W; Narayan O
    AIDS Res Hum Retroviruses; 1999 Mar; 15(4):391-4. PubMed ID: 10082123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques.
    Miyake A; Akagi T; Enose Y; Ueno M; Kawamura M; Horiuchi R; Hiraishi K; Adachi M; Serizawa T; Narayan O; Akashi M; Baba M; Hayami M
    J Med Virol; 2004 Jul; 73(3):368-77. PubMed ID: 15170630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A noninfectious simian/human immunodeficiency virus DNA vaccine that protects macaques against AIDS.
    Singh DK; Liu Z; Sheffer D; Mackay GA; Smith M; Dhillon S; Hegde R; Jia F; Adany I; Narayan O
    J Virol; 2005 Mar; 79(6):3419-28. PubMed ID: 15731236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies.
    Ruprecht RM; Hofmann-Lehmann R; Smith-Franklin BA; Rasmussen RA; Liska V; Vlasak J; Xu W; Baba TW; Chenine AL; Cavacini LA; Posner MR; Katinger H; Stiegler G; Bernacky BJ; Rizvi TA; Schmidt R; Hill LR; Keeling ME; Montefiori DC; McClure HM
    Transfus Clin Biol; 2001 Aug; 8(4):350-8. PubMed ID: 11642027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenic simian/human immunodeficiency virus SHIV(KU) inoculated into immunized macaques caused infection, but virus burdens progressively declined with time.
    Silverstein PS; Mackay GA; Mukherjee S; Li Z; Piatak M; Lifson JD; Narayan O; Kumar A
    J Virol; 2000 Nov; 74(22):10489-97. PubMed ID: 11044093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
    Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
    J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P).
    Kumar A; Lifson JD; Li Z; Jia F; Mukherjee S; Adany I; Liu Z; Piatak M; Sheffer D; McClure HM; Narayan O
    Virology; 2001 Jan; 279(1):241-56. PubMed ID: 11145906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective effects of nef-deleted SHIV or that having IFN-gamma against disease induced with a pathogenic virus early after vaccination.
    Enose Y; Kita M; Yamamoto T; Suzuki H; Miyake A; Horiuchi R; Ibuki K; Kaneyasu K; Kuwata T; Takahashi E; Sakai K; Shinohara K; Miura T; Hayami M
    Arch Virol; 2004 Sep; 149(9):1705-20. PubMed ID: 15593414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infected macaques that controlled replication of SIVmac or nonpathogenic SHIV developed sterilizing resistance against pathogenic SHIV(KU-1).
    Stephens EB; Joag SV; Atkinson B; Sahni M; Li Z; Foresman L; Adany I; Narayan O
    Virology; 1997 Aug; 234(2):328-39. PubMed ID: 9268165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection.
    Xu R; Srivastava IK; Kuller L; Zarkikh I; Kraft Z; Fagrouch Z; Letvin NL; Heeney JL; Barnett SW; Stamatatos L
    Virology; 2006 Jun; 349(2):276-89. PubMed ID: 16527321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3.
    Kent SJ; Dale CJ; Ranasinghe C; Stratov I; De Rose R; Chea S; Montefiori DC; Thomson S; Ramshaw IA; Coupar BE; Boyle DB; Law M; Wilson KM; Ramsay AJ
    Vaccine; 2005 Oct; 23(42):5009-21. PubMed ID: 15985317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralizing antibodies administered before, but not after, virulent SHIV prevent infection in macaques.
    Foresman L; Jia F; Li Z; Wang C; Stephens EB; Sahni M; Narayan O; Joag SV
    AIDS Res Hum Retroviruses; 1998 Aug; 14(12):1035-43. PubMed ID: 9718118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.
    Parren PW; Marx PA; Hessell AJ; Luckay A; Harouse J; Cheng-Mayer C; Moore JP; Burton DR
    J Virol; 2001 Sep; 75(17):8340-7. PubMed ID: 11483779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody.
    Burton DR; Hessell AJ; Keele BF; Klasse PJ; Ketas TA; Moldt B; Dunlop DC; Poignard P; Doyle LA; Cavacini L; Veazey RS; Moore JP
    Proc Natl Acad Sci U S A; 2011 Jul; 108(27):11181-6. PubMed ID: 21690411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies.
    Nishimura Y; Igarashi T; Haigwood N; Sadjadpour R; Plishka RJ; Buckler-White A; Shibata R; Martin MA
    J Virol; 2002 Mar; 76(5):2123-30. PubMed ID: 11836389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses.
    Kumar A; Lifson JD; Silverstein PS; Jia F; Sheffer D; Li Z; Narayan O
    Virology; 2000 Aug; 274(1):149-64. PubMed ID: 10936096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of a SHIV 89.6 proviral DNA vaccine against mucosal SIVmac239 challenge.
    Busch M; Abel K; Li J; Piatak M; Lifson JD; Miller CJ
    Vaccine; 2005 Jul; 23(31):4036-47. PubMed ID: 15963361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys.
    Julg B; Sok D; Schmidt SD; Abbink P; Newman RM; Broge T; Linde C; Nkolola J; Le K; Su D; Torabi J; Pack M; Pegu A; Allen TM; Mascola JR; Burton DR; Barouch DH
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope.
    Barnett SW; Srivastava IK; Kan E; Zhou F; Goodsell A; Cristillo AD; Ferrai MG; Weiss DE; Letvin NL; Montefiori D; Pal R; Vajdy M
    AIDS; 2008 Jan; 22(3):339-48. PubMed ID: 18195560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the pathogenic KU-SHIV model of acquired immunodeficiency syndrome in macaques.
    Joag SV; Li Z; Foresman L; Pinson DM; Raghavan R; Zhuge W; Adany I; Wang C; Jia F; Sheffer D; Ranchalis J; Watson A; Narayan O
    AIDS Res Hum Retroviruses; 1997 May; 13(8):635-45. PubMed ID: 9168232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.